Вы находитесь на странице: 1из 2

Elder Pharma Posts Higher Net Profit Of Rs. 15.

83 Cr For Q3 Ended Dec-10 - Up By


3%
* Company gets accreditation from Ministry of Health, Japan for its Patalganga p
lant.
* Launches Shelcal K.
Mumbai, India, February 09, 2011 -- Elder Pharmaceuticals Ltd (NSE- ELDERPHARM)
an integrated pharmaceuticals company headquartered in Mumbai has posted excelle
nt results for the third quarter ended Dec 2010 (Q3 FY2011). As per the consolid
ated unaudited provisional results taken on record on Feb 7th, 2011, the income
from operations has gone up to Rs 251.54 Crore for Q3 FY2011 as compared to Rs.
179.99 Crore during the corresponding quarter in the previous year. The consolid
ated operating profit (PBIDT) too has gone up to Rs. 45.01 Crore for Q3 FY2011 r
eflecting a growth of 23% over the previous corresponding quarter's figure of Rs
. 36.50 Crore. The consolidated Net Profit too has gone up to Rs. 15.83 Crore (p
revious year's quarter - Rs. 15.37 Crore) - a spurt of 3%. The consolidated EPS
on a non - annualized basis comes to Re. 8.34.
For the nine months ended Dec 2010, the consolidated sales turnover is Rs. 656.4
8 Cr (previous nine months - Rs. 512.28 Cr) up by 28% and the net profit is Rs.
46.19 Cr (previous nine months - Rs 38.45 Cr) up by 20%.
During the quarter under review, Elder Pharma ( http://www.elderindia.com ) rece
ived accreditation from Ministry of Health-Japan for its API [Active Pharmaceuti
cal Ingredients] plant at Patalganga, Maharashtra opening up the fast-growing Ja
panese markets for the companies products. This accreditation is considered to b
e very difficult to get as only companies with the very best of infrastructure a
nd quality are able to get this accreditation. "This accreditation for the API p
lant is a step towards strengthening Elder's position as a supplier of APIs and
intermediates in the Japanese market," informed Mr. Alok Saxena, Director, Elder
Pharmaceuticals Limited.
The Company has launched Shelcal K which is a combination of Calcium with high d
osage of Vitamin K, prescribed in severe established cases of osteoporosis with
a pre-existing vertebral fracture. Contribution from the Langa Road facility (Ut
taranchal), launch of new products, penetration into Rural & Semi-Urban markets
and strong growth in the traditional products have contributed to the company's
better working.
Elder Pharmaceuticals has presence in niche therapeutic segments like Women's he
althcare, Wound care, Nutraceuticals /vitamin Supplements, Cardiology, Diabetes,
Dermatology, Antibiotics and neurology. It is the market leader in calcium supp
lements (Shelcal), wound healing and injectable B12 vitamin. The company has a j
udicious mix of drug formulations, and active pharma ingredients (APIs). It has
6 manufacturing plants in India located in Maharashtra, Uttarakhand & Himachal P
radesh. The company has a state-of-the-art Research & Development Centre at Navi
Mumbai which is recognized by the Department of Scientific & Industrial Researc
h, Ministry of Science & Technology. ( http://www.elderindia.com ).
Press & Media Contact:
Mitesh M Kapadia
Sentinel Public Relations Pvt Ltd / Sentinel Advertising Services
B-603, Samajdeep, Near Bhanu Park/Seasons Restaurant
Adukia Road, Off S V Road
Kandivli (W), Mumbai 400 067 India
Mob: +91 98205 03876
Tel: (022) 28625131/32
Fax: (022) 28625133
mitesh@publicrelationindia.com
http://www.publicrelationindia.com
http://www.elderindia.com

Вам также может понравиться